Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure

17 dogs with pacing-induced cardiomyopathy

LU 135252 (endothelin type A receptor antagonist) 50 mg/kg orally daily starting at day three of pacing and continued for the remainder of the three weeks of pacing

Matching placebo

Hemodynamic parameters (mean pulmonary artery pressure, left ventricular end diastolic pressure, cardiac output) and plasma norepinephrine levels at two weekssurrogate